A Phase 1 Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands in Patients With Acute Myeloid Leukemia (AML)/Advanced Myelodysplastic Syndrome (MDS-RAEB) and Multiple Myeloma

Trial Profile

A Phase 1 Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands in Patients With Acute Myeloid Leukemia (AML)/Advanced Myelodysplastic Syndrome (MDS-RAEB) and Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Dec 2016

At a glance

  • Drugs NKR 2 (Primary)
  • Indications Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes
  • Focus Adverse reactions; First in man
  • Sponsors Celdara Medical
  • Most Recent Events

    • 06 Dec 2016 Results of phase I portion of this study (n=11) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 07 Nov 2016 According to Celyad media release, results which will be presented during a poster session at the 58th American Society of Hematology (ASH) Annual Meeting.
    • 09 Sep 2016 According to Celyad Media Release phase I portion of this study is completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top